Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Shelton Capital Management

Shelton Capital Management boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,631 shares of the pharmaceutical company's stock after buying an additional 647 shares during the period. Shelton Capital Management's holdings in Vertex Pharmaceuticals were worth $22,000,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in VRTX. EP Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals by 5.0% during the 3rd quarter. EP Wealth Advisors LLC now owns 5,153 shares of the pharmaceutical company's stock worth $2,397,000 after purchasing an additional 244 shares during the last quarter. Dunhill Financial LLC lifted its stake in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares in the last quarter. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the third quarter worth about $33,000. MML Investors Services LLC grew its stake in Vertex Pharmaceuticals by 27.7% during the 3rd quarter. MML Investors Services LLC now owns 48,077 shares of the pharmaceutical company's stock valued at $22,360,000 after acquiring an additional 10,437 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its holdings in Vertex Pharmaceuticals by 4.6% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 154,894 shares of the pharmaceutical company's stock valued at $72,038,000 after acquiring an additional 6,831 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Remove Ads

Vertex Pharmaceuticals Stock Up 1.8 %

VRTX stock traded up $8.73 during midday trading on Friday, hitting $484.22. The company's stock had a trading volume of 1,574,131 shares, compared to its average volume of 1,326,055. The firm has a 50-day simple moving average of $484.84 and a 200-day simple moving average of $464.28. The firm has a market capitalization of $124.34 billion, a P/E ratio of -220.10, a PEG ratio of 2.11 and a beta of 0.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Barclays upped their price target on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 11th. Scotiabank raised their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research note on Tuesday, February 11th. Oppenheimer cut shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 19th. Piper Sandler decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Finally, Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a report on Monday, December 16th. Ten research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $512.41.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock valued at $2,121,012 over the last 90 days. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.